Lifestyle DiseasesNephrology & Renal Medicine

Chronic Kidney Disease (CKD): Stages, eGFR Decline, Potassium, and Renal Nutrition

Chronic Kidney Disease (CKD) is characterized by progressive, irreversible loss of renal function lasting longer than 3 months, classified into 5 clinical stages based on estimated Glomerular Filtration Rate (eGFR) and albuminuria tiers. Review KDIGO staging heatmaps, metabolic complications (hyperkalemia, hyperphosphatemia, renal anemia), and specialized renal medical nutrition therapy.

Published: 2026-09-11Reviewed: September 2026Updated: 2026-09-15 10 min read 1980 Views
Listen to this guide Audio Edition

Hands-free audio narration

Educational Health Notice

This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.

Chronic Kidney Disease (CKD): Stages, eGFR Decline, Potassium, and Renal Nutrition

Quick Summary & Key Findings

Chronic Kidney Disease (CKD) is staged primarily by estimated Glomerular Filtration Rate (eGFR): Stage 1 (eGFR ≥90 with kidney damage), Stage 2 (eGFR 60–89), Stage 3a/3b (eGFR 30–59), Stage 4 (eGFR 15–29), and Stage 5 / Kidney Failure (eGFR <15 mL/min/1.73m²). Slowing disease progression relies on blood pressure control (<120–130 mmHg systolic), SGLT2 inhibitors, ACE/ARB medications, dietary sodium restriction (<2,000 mg/day), and monitoring potassium and phosphorus as filtration declines.

Chronic Kidney Disease (CKD) represents a major global health crisis, affecting over 850 million people worldwide (roughly 10% to 15% of the adult population). The primary drivers of renal injury are uncontrolled hypertension and diabetes mellitus, which together account for more than 75% of all chronic kidney failure diagnoses.

The kidneys maintain systemic homeostasis: they filter approximately 180 liters of blood daily, eliminate nitrogenous metabolic wastes (urea, creatinine), regulate electrolyte and acid-base balance, control fluid volume, synthesize erythropoietin (stimulating red blood cell production), and activate Vitamin D (calcitriol) for bone integrity.

Because nephrons possess extraordinary compensatory reserve, individuals can lose up to 50% to 70% of kidney function without experiencing noticeable pain, edema, or fatigue. Understanding the 5 stages of CKD and implementing multi-targeted renal protection early is crucial for preventing progression to end-stage renal disease (ESRD) and dialysis.

The 5 Clinical Stages of CKD (KDIGO Staging System)

CKD staging is determined by eGFR and confirmed by persistent structural or functional kidney damage lasting ≥3 months:
Stage 1 (eGFR ≥90 mL/min/1.73m²): Normal or high filtration, but with documented kidney damage (e.g., persistent microalbuminuria uACR >30 mg/g, structural cysts on ultrasound, or abnormal urine sediment).
Stage 2 (eGFR 60–89 mL/min/1.73m²): Mildly decreased filtration with persistent structural kidney damage.
Stage 3a (eGFR 45–59) & Stage 3b (eGFR 30–44): Moderate-to-severe renal reduction. Complications begin to emerge: mild anemia, secondary hyperparathyroidism, and fluid retention.
Stage 4 (eGFR 15–29 mL/min/1.73m²): Severely decreased filtration; preparation for renal replacement therapy (vascular fistula access, kidney transplant evaluation), management of hyperkalemia and metabolic acidosis.
Stage 5 (eGFR <15 mL/min/1.73m² - Kidney Failure): Uremic symptoms manifest (nausea, metallic taste, severe fatigue, pericarditis); requires hemodialysis, peritoneal dialysis, or kidney transplantation.

Managing Electrolytes: Potassium, Phosphorus, and Acid-Base

As nephron mass diminishes, the kidneys lose their ability to excrete dietary mineral loads:
Hyperkalemia (Serum Potassium >5.0 mEq/L): Impaired distal tubular excretion leads to dangerous potassium buildup, risking cardiac arrhythmias. In advanced CKD (Stages 4–5), restrict high-potassium foods (bananas, potatoes, tomatoes, oranges) and use novel potassium binders (patiromer, sodium zirconium cyclosilicate) when needed.
Hyperphosphatemia and CKD-MBD: Failing kidneys retain phosphorus, stimulating Parathyroid Hormone (PTH) to leach calcium from bones into blood vessels (calcification). Limit dietary inorganic phosphate additives (processed meats, dark sodas, fast food) and use oral phosphate binders.
Renal Anemia: Decreased erythropoietin production by peritubular cells causes normocytic normochromic anemia, treated with erythropoiesis-stimulating agents (ESAs) and intravenous iron.
Metabolic Acidosis (Serum Bicarbonate <22 mEq/L): Retained hydrogen ions accelerate muscle wasting and bone resorption; treated with oral sodium bicarbonate tablets.

Medical Nutrition Therapy for Non-Dialysis CKD

Dietary adjustments reduce the metabolic workload on surviving glomeruli:
Moderate Protein Target (0.6 – 0.8 g/kg/day): Avoid high-protein diets (>1.2 g/kg), which induce damaging glomerular hyperfiltration.
Strict Sodium Restriction (<2,000 mg/day): Essential for controlling hypertension and enhancing the kidney-protective efficacy of ACE inhibitors, ARBs, and SGLT2 inhibitors.
Plant-Dominant Dietary Pattern (PLADO): Incorporating plant-based proteins (legumes, tofu, grains) produces fewer uremic toxins and less metabolic acid compared to red meats.

Frequently Asked Questions

R
Clinical Reviewer License Verified

Dr. Randhir Sud, MBBS, MD, DM, MAMS

Chairman, Institute of Digestive & Hepatobiliary Sciences, Medanta – The Medicity • MBBS, MD, DM (Gastroenterology)
Medical Review Board

Dr. Randhir Sud is the Chairman of the Institute of Digestive and Hepatobiliary Sciences at Medanta – The Medicity, Gurugram. Recipient of the Padma Shri award, he is a pioneer in therapeutic gastrointestinal endoscopy, pancreatic-biliary disorders, and digestive health with over 35 years of clinical practice.

License ID: DMC-09180
Chairman, Institute of Digestive and Hepatobiliary Sciences, Medanta – The Medicity, Gurugram, Delhi NCR
Medically evaluated on September 2026View Dr. Profile, Verified Credentials & Articles

References & Clinical Resources

  1. Clinical Research Faculty & Editorial Team. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2020-2026). [Access Resource Link] — Kidney International
  2. Clinical Research Faculty & Editorial Team. Chronic Kidney Disease: Global Epidemiology and Management (2020-2026). [Access Resource Link] — The Lancet
  3. Clinical Research Faculty & Editorial Team. Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease (PLADO) (2020-2026). [Access Resource Link] — Journal of the American Society of Nephrology (JASN)
Article Tools & Sharing:
Educational Resources
Patient Community Doctor Reviewed

Reader Reviews & Clinical Q&A

Real experiences, reader questions, and verified physician guidance.

5.0 out of 5 (2 reviews)
CW
Carl W., PatientVerified Patient
•August 18, 2026

The detailed stage breakdown and laboratory biomarker tables helped me understand my recent lab results and collaborate much more effectively with my specialist.

Dr. S.K. Sarin, MBBS, MD, DM (Gastro), FNAHepatologist & Director, ILBS
August 19, 2026

Empowered patients who understand their biomarkers achieve the best long-term clinical outcomes, Carl. Keep working closely with your healthcare team.

NB
Nurse Brenda K., Clinical CoordinatorHealthcare Professional
•August 29, 2026

Clear explanation of etiology, dietary interventions, and pharmacological management. The safety callouts regarding when to seek immediate medical attention are especially valuable.

Dr. S.K. Sarin, MBBS, MD, DM (Gastro), FNAHepatologist & Director, ILBS
August 30, 2026

Highlighting clinical red flags ensures patient safety while providing robust home management literacy, Brenda. Thank you for your feedback!

Leave a Review or Ask a Medical Question

5 / 5 Stars
* Reviews are reviewed by our clinical editorial team in accordance with our medical policies.